BaseLaunch
VC Fund
Allschwil, Switzerland
BaseLaunch is a VC fund in Allschwil focused on Biotechnology and Therapeutics. The BaseLaunch accelerator supports carefully selected ventures over the course of 15 months and runs in two phases. It provides non-dilutive funding, no strings attached access to its Healthcare Partners, knowledge from highly experienced advisors, as well as a state-of-the-art infrastructure. Furthermore, Baselaunch embeds the ventures deeplywithin the Basel region, one of Europe’s finest biotech ecosystem. Baselaunch is backed by five industry leaders — Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and Roivant Sciences — as well as by other public and private partners.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 91%
Last updated:
For AI agents: llms.txt
Industries BaseLaunch invests in
Stages BaseLaunch invests in
Countries BaseLaunch invests in
Investment Focus
Industry
- Biotechnology 9 (82%)
- Therapeutics 5 (45%)
- Medical 2 (18%)
- Health Care 2 (18%)
- Life Science 2 (18%)
Stage
- Pre-Seed 5 (45%)
- Grant 4 (36%)
- Seed 1 (9%)
- Convertible Note 1 (9%)
Country
- Switzerland 8 (73%)
- Spain 1 (9%)
- Brazil 1 (9%)
- Germany 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cancentus
|
Cancentus is a cancer treatment company that provides AI-based disease discovery solutions. | $635.7K / Convertible Note / Apr 26, 2026 | |
|
Umlaut.Bio
|
Umlaut.Bio is a spinout of the European Molecule Biology Laboratory (EMBL), is pursuing tRNA targets for treatment of cancer and immunological diseases. | $3.5M / Pre-Seed / Feb 20, 2026 | |
IAstein
|
A IAstein é uma startup brasileira de EdTech que desenvolve soluções baseadas em Inteligência Artificial generativa para a resolução automatizada e explicada de questões. Nosso sistema utiliza NLP, modelos LLM e algoritmos de machine learning para fornecer respostas claras, fundamentadas e com justificativas — tornando o processo de estudo maisinteligente, rápido e personalizado.Fundada em janeiro de 2024, em Salvador (BA), a IAstein já impactou centenas de usuários em fase beta e foi selecionada por programas de aceleração regional. Em março de 2025, recebemos um investimento pré-seed de R$ 500.000 de um grupo de investidores-anjo e uma aceleradora focada em IA e educação. | $17.7K / Pre-Seed / Jul 01, 2024 | |
NXI Therapeutics
|
NXI Therapeutics specializes in the development of innovative immunosuppressive drugs aimed at treating autoimmune diseases and facilitating organ transplantation. The company focuses on creating drugs that offer high efficacy in managing these conditions. With a team led by CEO Ruben Herrendorff, who has extensive experience in preclinical andearly clinical drug research and development, particularly in autoimmune and neuromuscular diseases, NXI Therapeutics is at the forefront of addressing complex medical challenges. The company operates within the biotechnology industry and is committed to advancing the field through its research initiatives. | $4M / Pre-Seed / Jun 18, 2024 | |
Phialogics
|
Phialogics is a preclinical biotech business with a focus on developing next-generation biologics to balance the immune response in both acute and long-term inflammation. | $549.5K / Grant / Oct 06, 2023 | |
Onena Medicines
|
Onena Medicines is a biotechnology company that creates innovative biological medicines to address the large unmet clinical need for breast cancer and other serious orphan illness. | $549.5K / Grant / Oct 06, 2023 | |
FimmCyte
|
FimmCyte develops a novel disease modifying treatments for fibro-inflammatory diseases, starting with Endometriosis. | $549.5K / Grant / Oct 06, 2023 | |
Salvina Therapeutics
|
Salvina Therapeutics is working to break through efficacy barriers in inflammatory and autoimmune illnesses. The business discovered a novel epitope for specifically targeting TNF, culminating in the development of antibodies with a novel mode of action. | $544.7K / Grant / Oct 02, 2023 | |
Engimmune Therapeutics
|
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors. | $545.9K / Pre-Seed / Feb 21, 2022 | |
Aukera Therapeutics
|
Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein-related diseases such as cancer and neurogenerative diseases. Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel. | $540.2K / Pre-Seed / Feb 15, 2022 | |
| See all 11 investments → | |||
Co-Investors
Kickfund
1 deal together
Venture Kick
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does BaseLaunch invest in?
BaseLaunch invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Pre-Seed and Grant stage. Most of the 11 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did BaseLaunch last invest?
The most recent investment recorded for BaseLaunch closed in Apr 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
